Weekly Recap | HANSOH PHARMA -9.32%, consensus target above spot

LongbridgeAII'm LongbridgeAI, I can summarize articles.

The Week

Hansoh Pharma fell 9.32% this week to close at HK$30.74, underperforming the Hang Seng Index by about 3.67 percentage points, with the benchmark down 5.65%. The selling was consistent rather than sharp. The stock opened higher on Monday and hit a weekly high of HK$34.02, then drifted lower over the next three sessions. Thursday saw the steepest drop, with the price touching HK$30.60, just above the 60-session range low of HK$30.50. Weekly amplitude came in at 10.31%, while average daily volume of roughly 9.0m shares sat 10.7% below the 60-session median.

Key Events

The week’s news split between sector policy and company-specific progress. On 19 November, Citi noted that the 2026 NRDL negotiation results had been released, with drugmakers describing price cuts as mild and manageable. The next morning Hansoh Pharma fell nearly 5% as the market processed the implications for pricing. Later on 20 November, the company announced that the National Medical Products Administration had accepted its new drug application for socrodeucitinib (HS-10374) as a treatment for psoriasis. If approved, the product would broaden Hansoh’s pipeline in immunology and rare disease.

Analyst Ratings

Coverage sits at 23 brokers, with 17 rating the stock buy and 6 rating it outperform. There are no neutral, underweight or sell ratings. The consensus recommendation is strong buy, with a consensus target price of HK$48.43, roughly 57.5% above the latest close. Targets range from HK$43.01 to HK$55.49, a spread of about 29% that points to some divergence among analysts. Within the pharmaceutical sector, Hansoh ranks third among 29 comparable names by the size and attention of its broker coverage.

The Week Ahead

Hansoh Pharma reports third-quarter fiscal 2026 results after market close on 26 November. With NRDL pricing updates already in the market this week, attention will shift to revenue growth, sales of key products, and any company commentary on next steps for the psoriasis drug candidate.

In Short

The stock pulled back this week while the sell-side stance remained strongly positive, with a consensus target far above spot. At the same time, the latest session’s large-lot flow showed net selling, and the stock trades around 24 times earnings, a relatively high level for its recent range. That gap between broker targets and current positioning leaves next week’s quarterly report as the key test for whether the pullback deepens or stabilises.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.

Source: Weekly Review The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.